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Abstract
“Two-cysteine” peroxiredoxins are antioxidant enzymes that exert a cytoprotective effect in many
models of oxidative stress. However, under highly oxidizing conditions they can be inactivated
through hyperoxidation of their peroxidatic active site cysteine residue. Sulfiredoxin can reverse
this hyperoxidation, thus, reactivating peroxiredoxins. Here we review recent investigations that
have shed further light on sulfiredoxin’s role and regulation. Studies have revealed sulfiredoxin to
be a dynamically regulated gene whose transcription is induced by a variety of signals and stimuli.
Sulfiredoxin expression is regulated by the transcription factor AP-1, which mediates its up-
regulation by synaptic activity in neurons, resulting in protection against oxidative stress.
Furthermore, sulfiredoxin has been identified as a new member of the family of genes regulated
by Nuclear factor erythroid 2-related factor (Nrf2) via a conserved cis-acting antioxidant response
element (ARE). As such, sulfiredoxin is likely to contribute to the net antioxidative effect of small
molecule activators of Nrf2. As discussed here. the proximal AP-1 site of the sulfiredoxin
promoter is embedded within the ARE, as is common with Nrf2 target genes. Other recent studies
have shown that sulfiredoxin induction via Nrf2 may form an important part of the protective
response to oxidative stress in the lung, preventing peroxiredoxin hyperoxidation and, in certain
cases, subsequent degradation. We illustrate here that sulfiredoxin can be rapidly induced in vivo
by administration of CDDO-TFEA, a synthetic triterpenoid inducer of endogenous Nrf2, which
may offer a way of reversing peroxiredoxin hyperoxidation in vivo following chronic or acute
oxidative stress.
Introduction
Peroxiredoxins (Prxs) are a ubiquitous family of peroxidases with cytoprotective and
antioxidative effects (Immenschuh and Baumgart-Vogt, 2005). The “two cystein” (2-Cys)
Prxs are the predominant Prx subfamily, comprising Prx I-IV (Wood et al., 2003) and have
an important antioxidative role in diverse cell systems (Wood et al., 2003; Immenschuh and
Baumgart-Vogt, 2005; Rhee et al., 2005). For example, in neuronal cells Prxs are protective
against Aβ toxicity (Yao et al., 2007), excitotoxicity (Hattori et al., 2003), oxygen-glucose
deprivation (Boulos et al., 2007), peroxide (Sanchez-Font et al., 2003; Fang et al., 2007),
and MPP+ toxicity (Qu et al., 2007). 2-Cys Prxs contain a peroxidatic cysteine residue,
oxidized by peroxides to cysteine sulfenic acid (-SOH). Cys-SOH then forms a disulfide
bond with the resolving cysteine, which is in turn reduced by thioredoxin(Wood et al.,
2003). Sometimes, under increased oxidative stress, Prx-SOH is further oxidized by
peroxide to sulfinic (-SO2H) acid, causing inactivation of peroxidase activity (Rhee et al.,
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2007). Prx-SO2H is not a substrate for the resolving cysteine and cannot be reduced by
thioredoxin. As such, Prx hyperoxidation to Prx-SO2H was thought to be irreversible.
Subsequently, it has been found that Prx-SO2H can be reduced back to the catalytically
active thiol form by two ATP-dependent reductases, sulfiredoxin (Biteau et al., 2003; Chang
et al., 2004) and sestrin 2 (Budanov et al., 2004). However, recent doubt has been cast on the
ability of sestrin 2 to catalyze this reaction (Rhee et al., 2009). Sulfiredoxin acts by
catalysing the ATP-dependent formation of a sulfinic acid phosphoric ester on Prx which is
then reduced by thiol equivalents such as thioredoxin. Sulfiredoxin (Jeong et al., 2006; Rhee
et al., 2007; Jonsson et al., 2008a; Jonsson et al., 2008b). Sulfiredoxin has also been shown
to have an additional enzymic activity: the reversal of glutathionylation (Findlay et al.,
2006)
Sulfiredoxin is an AP-1 target gene
The first report of direct transcriptional regulation of the sulfiredoxin promoter involved a
microarray-based search for glucose/cAMP regulated genes in Min6 insulin-secreting cells
(Glauser et al., 2007). Bioinformatics revealed a large number of potential AP-1 target genes
in the population of up-regulated genes, which included sulfiredoxin. AP-1 regulation of the
sulfiredoxin promoter was subsequently demonstrated (Glauser et al., 2007).
At the same time, our interest in sulfiredoxin arose through our investigation into the
regulation of intrinsic antioxidant defences in neurons. We found that synaptic activity,
acting via NMDA receptor (NMDAR) signaling, boosted antioxidant defences through a
coordinated pattern of gene expression that included the up-regulation of sulfiredoxin. Both
sulfiredoxin and sestrin 2 were induced by synaptic activity, which also promoted the
reduction of hyperoxidized peroxiredoxins (Papadia et al., 2008). Simultaneous knock-down
of sulfiredoxin and sestrin 2 promoted neuronal vulnerability of neurons to oxidative stress
(Papadia et al., 2008). In the light of recent studies it may be that induction of sulfiredoxin is
the more significant to neuroprotection than sestrin 2 (Rhee et al., 2009). Study of the
transcriptional regulation of sulfiredoxin in neurons revealed that it could be induced by
AP-1. Furthermore, we pin-pointed the sites of regulation to two cis-acting AP-1 consensus
sites (Papadia et al., 2008). Mutation of each AP-1 site in turn reduced transcriptional
activation of sulfiredoxin by synaptic activity, and mutation of both sites abolished induction
completely (Papadia et al., 2008). The proximal AP-1 site is completely conserved in
diverse mammalian species such as rodents, rats and cows, and humans. However, the distal
site, while well-conserved for the most part, has been lost from the primate lineage. As such,
AP-1 responsiveness of sulfiredoxin in humans may rely on this single site.
The direct regulation of sulfiredoxin by AP-1 acting via these two sites was confirmed in the
context of mouse epidermal cells. Here it was shown that 12-Otetradecanoylphorbol-13-
acetate (TPA)-mediated induction of sulfiredoxin was stimulated by AP-1 acting on these
sites (Wei et al., 2008). Expression of the widely-used inhibitor of AP-1 mediated gene
expression, TAM67 (a dominant-negative form of c-Jun (Brown et al., 1993)) both inhibited
synaptic activity-dependent induction of the sulfiredoxin promoter in neurons (Soriano et al.,
2008) as well as its induction by TPA in mouse JB6 cells (Wei et al., 2008).
Sulfiredoxin is an Nrf2 target gene
A known defence against oxidative insults is the induction of a group of genes encoding
antioxidative and drug-metabolizing enzymes (Kensler et al., 2007). These genes are
induced by a variety of small thiol-active molecules including the potent chemopreventive
agent 3H-1,2-dithiole-3-thione (D3T) (Nguyen et al., 2004; Kensler et al., 2007).
Transcriptional regulation of this group of genes is mediated by a cis-acting promoter
element termed the antioxidant response element (ARE), which recruits the transcription
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factor Nuclear factor erythroid 2-related factor (Nrf2) as a heterodimer with small Maf
proteins (Zhang, 2006). Nrf2 levels are constitutively low due to being targeted for
degradation by Kelch like ECH-associated protein (Keap)-1. Under conditions of oxidative
stress, Nrf2 degradation is slowed and Nrf2 accumulates in the nucleus and activates ARE-
containing genes, with a net antioxidative effect (Nguyen et al., 2004). Small molecule
activators of Nrf2 such as D3T also act by interfering with Keap1-mediated degradation.
Activation of Nrf2 and induction of ARE-driven defences is implicated in protecting against
a variety of diseases in many organs and tissues, including autoimmune diseases, cancer,
cardiovascular, neurodegenerative disease and ischemia (Lee et al., 2005; Shih et al., 2005;
Giudice and Montella, 2006; Zhang, 2006).
We found that in cortical neurons, expression of Nrf2 rendered them highly resistant to
peroxide-induced apoptosis in a cell-autonomous manner (Soriano et al., 2008). Moreover,
treatment with the Nrf2 activator D3T inhibited the formation of inactivated, hyperoxidized
peroxiredoxins following oxidative trauma, and protected neurons against oxidative stress.
In both neurons and glia, Nrf2 expression and treatment with chemopreventive Nrf2
activators, including D3T, sulforaphane and tBHQ, up-regulated expression of sulfiredoxin
(Soriano et al., 2008). Analysis of the rat sulfiredoxin promoter revealed a sequence near to
the transcription start site (TCACCCTGAGTCAGCG) which resembled an ARE. This
includes a near-perfect match for the established consensus (TMAnnRTGA(Y/G)nnnGCR)
(Wasserman and Fahl, 1997) with the additional inclusion of two cytosine residues found to
be additionally important for ARE activity ((Nioi et al., 2003), TMACnRTGAYnCnGCR).
This sequence is remarkably well-conserved across mammalian species as diverse as
dolphins, mice and primates (Fig. 1).
In a paper published very shortly after ours, Biswal and coworkers also convincingly show
that sulfiredoxin expression is regulated by Nrf2 by a cis-acting ARE (Singh et al., 2009).
They found that sulfiredoxin expression was induced in the lung in response to cigarette
smoke in a Nrf2-dependent manner. Through overexpression and knock-down experiments
they demonstrated that sulfiredoxin played an important role in promoting resistance of lung
epithelial cells to peroxide-induced cell death.
Interestingly, the ARE proposed in this study is in a slightly different position, running in
the opposite orientation to the one we proposed, and offset by seven nucleotides (Fig. 1).
This motif, found by using a shorter consensus (RTGA(Y/G)nnnGCR) as a probe, is
conserved across many mammals, except mice. This sequence also includes a TMAnn motif
in the correct position, though neither of the two additional cytosine residues. In both studies
(Soriano et al., 2008; Singh et al., 2009), point mutations made to each ARE would be
predicted to impair the function of the other ARE. In all likelihood, both AREs are
functional.
The sulfiredoxin ARE contains an AP-1 site: target for both chemopreventive drugs and
tumour-promoting compounds
Another interesting facet of sulfiredoxin regulation is that its Nrf2- and AP-1-responsiveness
is contained within the same sequence. The proximal, conserved AP-1 site (TGAGTCA) is
contained within the ARE site we recently identified (TCACCCTGAGTCAGCG, (Soriano
et al., 2008)). Several AREs such as those in the promoters of human NQO1 and HMOX1
contain AP-1 like sequences and can respond to AP-1-activating stimuli, as well as Nrf2
(Nguyen et al., 2004). The composite ARE/AP-1 site on the sulfiredoxin promoter enables it
to respond both to small molecule Nrf2 activators (Soriano et al., 2008) as well as synaptic
activity (Papadia et al., 2008). A previous study had indicated that residues within the AP-1
consensus, but outside the traditional ARE consensus, may contribute to Nrf2-
responsiveness (Nioi et al., 2003). Indeed, we find that mutation of the 5th and 7th residues
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of the AP-1 site in the sulfiredoxin promoter (to TCACCCTGAGGCTGCG, mutated
residues in bold) had the effect of reducing Nrf2-responsiveness (Fig. 2). These residues
were though to be non-required ‘n’ residues within the ARE consensus but clearly influence
the efficacy of the sulfiredoxin ARE. Note that these residues are outside the ARE identified
by Biswal and coworkers, so residual Nrf2-responsiveness could be due to that ARE, as well
as residual activity of the mutated ARE.
An apparent paradox associated with genes responsive to both Nrf2 and AP-1 is that while
the former are targets of chemopreventive compounds, the latter is a target of certain tumor-
promoting agents, such as TPA (Wei et al., 2008). Indeed, in the context of TPA stimulation,
sulfiredoxin expression via AP-1 was found to be involved in cellular transformation (Wei et
al., 2008). Thus, while sulfiredoxin may contribute to the chemopreventive effects of Nrf2
activating compounds that act to detoxify reactive intermediates of carcinogens, and boost
antioxidant defenses, in the context of global AP-1 activation, its antioxidant properties
seem to have a different effect.
Pharmacological manipulation of sulfiredoxin in vivo
In addition to the aforementioned report of up-regulation of sulfiredoxin in the lung by
cigarette smoke via Nrf2 (Singh et al., 2009), a further study also demonstrated Nrf2-
dependent induction of sulfiredoxin expression in the lung-this time in response to
hyperoxia (Bae et al., 2009). Hyperoxia induced the hyperoxidation of mitochondrial Prx III
and promoted the degradation of Prx III in Nrf2-deficient mice that failed to respond to
hyperoxia with an induction of sulfiredoxin. This raises the possibility that in the absence of
sulfiredoxin, hyperoxidized Prx III is vulnerable to proteolysis. The importance of
sulfiredoxin’s role at the mitochondria was further illuminated by another recent study (Noh
et al., 2009). It was demonstrated that sulfiredoxin translocates from the cytoplasm to
mitochondria in response to oxidative stress, where it promotes the reduction of
hyperoxidized Prx III. Furthermore, mitochondrially targeted sulfiredoxin was found to be
anti-apoptotic, protecting mitochondria from oxidative damage and loss of membrane
potential (Noh et al., 2009).
These recent studies support the notion that sulfiredoxin is an important part of the
protective response against oxidative stress in the lung (Bae et al., 2009; Singh et al., 2009),
a response which also involves the induction of other antioxidative Nrf2 target genes
(Kensler et al., 2007). Perhaps significantly, sulfiredoxin levels are depleted in patients with
advanced chronic obstructive pulmonary disorder (Singh et al., 2009). This raises the
possibility that pharmaceutical up-regulation of sulfiredoxin expression may represent a
therapeutic strategy. To investigate this, we treated mice with a known inducer of Nrf2: a
synthetic triterpenoid called 1[2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]
trifluoroethylamide (CDDO-TFEA (Yates et al., 2007)), derivatives of which have been
found to have potent cytoprotective, chemopreventive and anti-inflammatory effects (Liby et
al., 2007). CDDO-TFEA was administered intraperitoneally to adult rats which resulted in
the rapid induction of sulfiredoxin expression in the lung. A 6-fold induction of expression
was observed at only 6 h post-administration (Fig. 3). Induction in the liver was even
stronger (around 20-fold, data not shown) Thus, pharmaceutical induction of sulfiredoxin in
the lung is achievable, and may slow the progression of chronic oxidative lung disorders, in
concert with other Nrf2 target genes.
Conclusions
The regulation of sulfiredoxin by two overlapping AREs facilitates its rapid transcriptional
induction by both oxidative stress and small molecule activators of Nrf2. This Nrf2-
responsiveness is observed in a variety of tissue types and is likely to be highly conserved
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within mammals. Sulfiredoxin is likely to be an important contributor to the cytoprotective
and chemopreventive effects of Nrf2 activation.
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Fig. 1. Schematic showing the high conservation of the Nrf2-responsive region of the mammalian
sulfiredoxin promoter
ARE(1) and ARE(2) identified by Soriano et al. (2008) and Singh et al. (2009) respectively.
Numbers indicate the position of the ARE relative to the transcription start site in humans.
Note that position is also well conserved (ARE position is at −232 (humans) −256 (rats),
−211 (mice)). Red letters indicate maximum conservation. Boxed region indicates AP-1
response element (see text for further details).
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Fig. 2. Mutation of residues supposedly specific to the AP-1 site influence Nrf2-responsiveness of
the sulfiredoxin ARE/AP-1 composite element
A) Schematic showing the mutations made to the consensus AP-1 site embedded within the
ARE identified by Soriano et al. (2008). B) The mutations performed reduce the Nrf2-
responsiveness of the sulfiredoxin promoter. Average of four independent experiments is
shown. Mutagenesis, transfection and luciferase assays were all performed as described
(Papadia et al., 2008).* P<0.05, Paired Student T-test.
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Fig. 3. Sulfiredoxin expression can be induced in vivo by the Nrf2 activator CDDO-TFEA
CDDO-TFEA (10% DMSO, 10% Cremophor-EL, 80% PBS) or vehicle only was injected
intraperitoneally into adult mice at a dose of 20 μmol/kg. At 6 hours following injection, the
animals were sacrificed and lungs harvested (n=4 for control and CDDO-TFEA). RNA was
extracted and subjected to qPCR analysis for Srxn1 expression as described (Soriano et al.,
2008). Expression of Srxn1 was normalized to GAPDH levels. * P<0.05, Student T-test.
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